| dc.contributor.author |
Taliyan, Rajeev |
|
| dc.date.accessioned |
2023-12-14T06:47:06Z |
|
| dc.date.available |
2023-12-14T06:47:06Z |
|
| dc.date.issued |
2017-10 |
|
| dc.identifier.uri |
https://linkinghub.elsevier.com/retrieve/pii/S0022510X17326953 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13420 |
|
| dc.description.abstract |
Insulin resistance has been reported as a strong risk factor for Alzheimer’s disease (AD). However the molecular mechanisms of association between these still remain elusive. Recently, elevated level of histone deacetylases (HDACs) and reduced histone acetylation has been reported in AD patients.Thus, targeting HDACs could provide a novel therapeutic strategy for treating these co-morbid condition. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Insulin |
en_US |
| dc.subject |
Histone deacetylases (HDACs) |
en_US |
| dc.title |
Histone deacetylase inhibitor, Valproic acid, ameliorates insulin resistance induced cognitive deficit in mice |
en_US |
| dc.type |
Article |
en_US |